Two patients achieved response; one attained complete response and their anti-HER2 treatment is ongoing (Table 2, ID:5, esophageal cancer, positive for HER2 in all three assays [CNV/mRNA/IHC], PFS: ≥42 months); one patient with cholangiocarcinoma was treated with anti-HER2 therapy on the basis of mRNA positivity alone, since CNV and IHC status was unknown because of insufficient tissue quantity; patient achieved partial response with PFS ≥24 months (Table 2; ID:7; Fig 4). Here, ERBB2 is linked to cholangiocarcinoma.